Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650298 · ClinicalTrials.gov registry record · NA
Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT01650298 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 64 participants.
The verdict
NCT01650298, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether it is safe to stop anticoagulation medication in patients with a history of atrial fibrillation (AF) based on information from a pacemaker or implantable cardioverter defibrillator (ICD).
Interventions
- OTHER Drug (Direct thrombin or Factor Xa inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-01 |
| Est. Completion | 2017-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01650298
The ClinicalTrials.gov registry entry for NCT01650298 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug (Direct thrombin or Factor Xa inhibitor) is the first listed.
NCT01650298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01650298 about?
NCT01650298 is a clinical study titled "Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation". The purpose of this study is to determine whether it is safe to stop anticoagulation medication in patients with a history of atrial fibrillation (AF) based on information from a pacemaker or implantable cardioverter defibrillator (ICD).
What is the current status of trial NCT01650298?
This trial is currently terminated. It is a NA study. The enrollment target is 64 participants. The study started on 2013-01. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01650298?
The interventions under investigation include: Drug (Direct thrombin or Factor Xa inhibitor) (OTHER).
Who is sponsoring clinical trial NCT01650298?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.